EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real-world outcomes of Citrobacter freundii , Klebsiella aerogenes, and Enterobacter cloacae bacteremia treatment (ROCKET): a contemporary analysis of treatment strategies

Jasanjeet Jawanda, Ryan K Shields, G K Balasubramani, Lloyd Clarke, Hannah Creager, Bonnie A Falcione, Rachel Marini, Matthew O’Donnell, Lingyi Peng, Sunish Shah

Journal of Antimicrobial Chemotherapy · 2026-11-03 · 81 (12)

DOI: 10.1093/jac/dkag377 ↗
AbstractBibliografische Angaben

Abstract

Abstract Objectives To determine comparative effectiveness of piperacillin/tazobactam and cefepime for the treatment of bacteremia due to Enterobacterales at moderate risk for clinically significant AmpC production. Methods A retrospective multicentre study was conducted among adults with bacteremia due to Enterobacter cloacae complex, Klebsiella aerogenes, or Citrobacter freundii complex from 2017 to 2025. Treatment-emergent resistance was defined as a ≥4-fold MIC increase or a categorical change in susceptibility within 90 days. Results Seven hundred twenty-eight patients met inclusion criteria. The median (IQR) age was 67 years (55–74), and 35% (252/728) were immunocompromised. Cefepime was used for definitive therapy in 47% (342/728), followed by piperacillin/tazobactam in 18% (129/728) and carbapenems in 16% (115/728). Overall, 30-day mortality was 12% (88/728). Patients receiving piperacillin/tazobactam had a higher median (IQR) Pitt bacteremia score (2 [1–3] versus 1 [0–3], P=0.017) than those receiving cefepime, but rates of 30-day mortality (14% [18/129] versus 11% [37/342], P = 0.345) and relapsed infection between days 5–14 (3% [4/129] versus 2% [5/342], P = 0.266) were similar. After inverse probability of treatment weighting, 30-day mortality rates between patients treated with piperacillin/tazobactam and cefepime were not significantly different (HR 1.05, 95% CI 0.57–1.92). Treatment-emergent resistance to definitive therapy occurred in 1% (5/342), 2% (3/129), and 3% (4/115) of patients treated with cefepime, piperacillin/tazobactam, and carbapenems, respectively. Conclusions In the largest study to date of bacteremia due to E. cloacae complex, K. aerogenes, or C. freundii complex, treatment-emergent resistance was uncommon, and outcomes did not differ significantly between patients treated with piperacillin/tazobactam and cefepime.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →